BGOG-ov63/NIRVANA-1

Randomized Study of Paclitaxel-carboplatin Followed by Niraparib Compared to Paclitaxel-carboplatin-bevacizumab Followed by Niraparib+bevacizumab in Patients with Advanced Ovarian Cancer, Following a Front-line Complete Surgery

Open
Trial drug
Bevacizumab, niraparib
Grade
High grade
Prior lines
Frontline
Histology
Serous, Endometrioid
Phase
II

Treatment

This study consists of two different treatment options:

  • Paclitaxel/carboplatin + maintenance niraparib
  • Paclitaxel/carboplatin/bevacizumab + maintenance niraparib/bevacizumab


You will be randomly allocated to one of the treatment groups on a 1:1 ratio.

Treatment duration

Total bevacizumab duration of therapy is 15 months. The total duration of niraparib treatment is 2 years.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.